Newly revealed biological mechanisms that underlie the development of pulmonary arterial hypertension (PAH) support activating BMPR2, the protein mutated…
Articles by Steve Bryson, PhD
Supplemental long-term oxygen therapy is the only effective treatment for people with pulmonary hypertension (PH) associated with chronic obstructive…
Breathing reserve, a measure of lung function calculated during exercise, predicted survival in adults with congenital heart disease associated with…
A passive leg raise is equally as effective as exercise in measuring pulmonary vascular distensibility, a physiological marker to predict…
Gene activity analysis of whole blood collected from people with pulmonary arterial hypertension (PAH) identified three patient subgroups associated…
PhaseBio Pharmaceuticals has voluntarily ended the Phase 2b trial testing its investigational pulmonary arterial hypertension (PAH) therapy pemziviptadil…
The use of the INOpulse combination drug-device therapy demonstrated a clinically meaningful reduction in pulmonary vascular resistance (PVR) —…
An orally available small molecule, BI113823, successfully reversed the progression of severe, advanced pulmonary arterial hypertension (PAH) in a…
Low birth weight has been linked to an increased risk of pulmonary hypertension (PH) in premature infants needing oxygen…
A large proportion of Swedish children younger than 7 who were diagnosed with pulmonary hypertension (PH) started treatment with…
Potential targets to treat pulmonary arterial hypertension (PAH) were identified by analyzing the gene activity of individual lung endothelial…
Seven long noncoding RNA molecules were found to be associated with the development of pulmonary hypertension (PH) in an…